Loading...
In a manufacturer-funded international randomized trial, 764 adults with bleeding from single gastric or duodenal ulcers received IV infusions of either high-dose esomeprazole or placebo. All patients exhibited endoscopic stigmata of recent bleeding, and nearly all underwent endoscopic treatment (i.e., injection therapy, thermal coagulation, or both). Investigators followed patients for clinically significant rebleeding (defined as >200 mL of vomited fresh blood or by vital sign and hemoglobin/hematocrit criteria, and endoscopic confirmation of blood in the stomach).
During the first 72 hours, the incidence of clinically significant recurrent bleeding was lower in the esomeprazole group than in the placebo group (6% vs. 10%). This benefit pe…